In the race to win FDA approval for a long-acting hemophilia A treatment, Novo Nordisk said its factor VIII therapy came through in a Phase III study, helping the Danish drugmaker play catchup in a three-way contest with Biogen Idec and Bayer.

…read more

Source: Novo touts a PhIII hemophilia win as it chases Biogen, Bayer


0 No comments